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Abstract An appreciable increase in GM3 with a concomitant
decrease in some neolacto-series gangliosides was observed
during differentiation of human colonic carcinoma HCT 116
cells induced by a differentiating agent. When the cells were
treated with brefeldin A (BFA), a striking increase in de novo
biosynthesis of GM3 and a decrease in biosynthesis of neolacto-
series gangliosides were observed after 6 h. Clear morphological
changes to differentiated epithelial cells and an arrest of cells in
the G0/G1 phase of the cell cycle were observed after 1 day of
treatment. Then the cells were led to apoptosis. This activity was
not affected by forskolin, which antagonizes the effects of BFA
on protein transport and the Golgi apparatus. These results
suggest that the differentiation-inducing activity of BFA might
be due to its modulatory effect on ganglioside biosynthesis, and
that a specific change in ganglioside pattern is an essential
prerequisite for induction of differentiation, providing a novel
target for differentiation therapy of cancer.
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1. Introduction
Glycosphingolipids (GSLs) are amphiphilic membrane
components. Gangliosides, GSLs containing sialic acid, are
considered to be involved in regulation of cell growth and
di¡erentiation [1]. We have shown that particular gangliosides
increase, depending on di¡erentiation direction, during di¡er-
entiation of human myelogenous leukemia cells induced by
di¡erentiating agents [2], and that such gangliosides them-
selves induce di¡erentiation in leukemia cells along the same
direction as their characteristic increases are observed [3,4].
These results have led to the hypothesis that speci¢c changes
of ganglioside pattern promote or induce terminal di¡erentia-
tion of leukemia cells and that defects in ganglioside expres-
sion might be one reason for di¡erentiation arrest of leukemia
cells at an immature stage.
We examined whether the hypothesis is applicable to other
malignant tumor cells using the human colonic carcinoma cell
line HCT 116 and found that human epithelial carcinoma cells
can also be induced to di¡erentiate into terminal di¡erentiated
cells by remodeling of the ganglioside pattern.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM) was obtained from
Iwaki Glass Co., Tokyo, Japan. Fetal bovine serum (FBS) was ob-
tained from HyClone, Logan, UT, USA. Tissue culture plasticware
was purchased from Becton Dickinson Labware, Lincoln Park, NJ,
USA. L-[3-14C]Serine was purchased from Amersham, UK. [4-14C]-
Cholesterol was purchased from NEN, Boston, MA, USA. Silica
gel 60 HPTLC plates were obtained from Merck, Darmstadt, Ger-
many. All other reagents were of analytical grade and were obtained
from Sigma, St. Louis, MO, USA. The human colonic carcinoma cell
line HCT 116 [5] was obtained from the American Type Culture
Collection.
2.2. Cell culture
HCT 116 cells were grown in Falcon 3082 tissue culture £asks in
DMEM containing 10% heat-inactivated FBS, 100 IU/ml penicillin,
and 100 Wg/ml streptomycin at 37‡C in a humidi¢ed atmosphere of
5% CO2 in air. Cells were counted with a hemocytometer, and via-
bility of cells was assessed by a dye exclusion test with erythrosin B.
Treatment of cells with sodium butyrate (NaBT) was carried out by
culturing them in the aforementioned medium containing 1 mM
NaBT. Brefeldin A (BFA) and forskolin were dissolved in 99.5%
ethanol at a concentration of 0.1 mg/ml (0.36 mM) and 50 mM re-
spectively, and added into the growth medium such that the ¢nal
ethanol concentration was 0.1%. Because this concentration of etha-
nol had no e¡ect on the cells, an ethanol control was not included in
this study.
2.3. Analysis of gangliosides
Total lipids were extracted sequentially from cells with the lower
phase of isopropyl alcohol/hexane/water (55:25:20, v/v/v), chloro-
form/methanol (1:1, v/v), and chloroform/methanol (2:1, v/v) [6]. In
the radiolabeling study, [4-14C]cholesterol was used as an internal
standard. Gangliosides were prepared by Folch’s partition and
DEAE-Sephadex A-25 chromatography from total lipids [7] and re-
solved by thin-layer chromatography on silica gel 60 HPTLC plates
with a solvent system composed of chloroform/methanol/0.5% CaCl2
(50:40:10, v/v/v). Measurement was done by densitometric scanning
[2].
2.4. De novo biosynthesis of gangliosides
HCT 116 cells were cultured in the presence of 300 nCi/ml L-
[3-14C]serine for various times [8]. After labeling, gangliosides were
prepared and resolved as described above. The radioactivity of each
band was determined using a BAS 2000 imaging analyzer (Fuji Film,
Tokyo, Japan).
2.5. Cell cycle analysis
DNA contents of cells were measured using the propidium iodide
(PI) staining method and a £ow cytometer [9]. The harvested cells
(2U106) were ¢xed in ice-cold 70% ethanol for 30 min. After washing
with phosphate-bu¡ered saline, cells were treated with 200 Wl of
0.5 mg/ml DNase-free RNase A at 37‡C for 20 min. Then the cells
were stained with 500 Wl of 0.05 mg/ml PI at 4‡C for 10 min, and
DNA content was analyzed with an Epics Elite £ow cytometer (Coult-
er, Hialeah, FL, USA).
2.6. Analysis of DNA fragmentation
DNA fragmentation was analyzed using agarose gel electrophoresis
[10]. Cells (1U106) were incubated at 50‡C for 90 min in a solution
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containing 10 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 10 mM EDTA,
0.1% sodium dodecyl sulfate, and 0.1 mg/ml proteinase K. Then
DNase-free RNase A was added to a ¢nal concentration of 20 Wg/
ml and incubated at 37‡C for 1 h. DNA was prepared by extraction
with phenol/chloroform/isoamyl alcohol (25:24:1) and precipitation
with ethanol. DNA (2 Wg) was loaded and electrophoresed in a
2.0% agarose gel containing 0.1 mg/ml ethidium bromide. DNA was
made visible under UV light.
3. Results
3.1. Di¡erentiation-related changes in ganglioside pattern of
HCT 116 cells
NaBT has been reported to induce HCT 116 cells to di¡er-
entiate [11]. When we treated HCT 116 cells with 1 mM
NaBT, gross morphological changes, including cell enlarge-
ment and £attening, were observed after 2 days of treatment
with growth suppression (Fig. 1A). There was no piling up of
treated cells in the culture. However, prominent nucleoli re-
mained in many NaBT-treated cells and nuclear condensation
was inadequate, suggesting that NaBT-treated cells are not
necessarily fully di¡erentiated cells.
As shown in Fig. 1B, gangliosides of HCT 116 cells con-
sisted of at least 13 molecular species, including ganglio-series
gangliosides GM3 (a doublet, band 1) and GM2 (a doublet,
band 2). The Rf values of gangliosides designated doublet
band 3, band 4, and band 6 were similar to those of the
sialosyl K2C6-lacto-neotetraosylceramide (IV6NeuAcnLc4)
doublet, sialosyl K2C3-lacto-norhexaosylceramide (VI3Neu-
AcnLc6), and sialosyl K2C6-lacto-norhexaosylceramide
(VI6NeuAcnLc6) of human erythrocytes respectively. The
presence of the IV6NeuAcnLc4 doublet and VI6NeuAcnLc6
in human colonic adenocarcinoma has been reported [7,12].
During NaBT-induced di¡erentiation of HCT 116 cells, GM3,
GM2, and unidenti¢ed bands 5 and 7 increased appreciably
while ganglioside corresponding to VI3NeuAcnLc6 decreased.
This suggests activation of the biosynthetic pathway of a-ser-
ies gangliosides [13] and inhibition of biosynthesis of some
neolacto-series gangliosides. An appreciable increase in GM3
(2.2-fold) and a decrease in VI3NeuAcnLc6 were observed
before morphological changes of NaBT-treated cells.
3.2. Arti¢cial remodeling of ganglioside pattern and its e¡ect
on HCT 116 cells
To explore the biological signi¢cance of ganglioside pattern
change during the induction of di¡erentiation, we tried to
arti¢cially induce such a ganglioside pattern in HCT 116 cells
and examine its e¡ect on them. A fungal metabolite, BFA, has
been reported to inhibit de novo biosynthesis of neolacto-ser-
ies glycolipids and to eventually increase GM3 [14]. We used
BFA to produce the same ganglioside pattern change as that
observed early in the NaBT-induced di¡erentiation of HCT
116 cells.
When HCT 116 cells were treated with 0.1 Wg/ml (0.36 WM)
BFA, we observed a striking increase (6.5-fold) in de novo
biosynthesis of GM3 and a concomitant decrease in the bio-
synthesis of other ganglio-series and neolacto-series ganglio-
sides after 6 h of treatment (Fig. 2A). This eventually gave rise
to a ganglioside pattern in BFA-treated cells, in which GM3
increased 5.2-fold (Fig. 2C). Following the change in de novo
biosynthesis of gangliosides, we observed clear morphological
changes to di¡erentiated epithelial cells [15], which included
cell £attening, formation of distinct intercellular junctions,
and nuclear condensation, with growth suppression in BFA-
treated cells after 1 day of treatment (Fig. 2B). The treated
cells then gradually became spherical with culture time, sug-
gesting changes toward apoptosis. Flow cytometric analysis
Fig. 1. Di¡erentiation-related changes in ganglioside pattern in HCT 116 cells. Di¡erentiation of HCT 116 cells was induced with 1 mM
NaBT. A: Morphological changes after 2 days of treatment. A con£uent culture was examined by phase-contrast light microscopy (magni¢ca-
tion, U90). B: Ganglioside pro¢les of treated cells. Ganglioside fractions corresponding to 5U106 cells were applied. Gangliosides of human
red blood cells (RBC) and a mixture of bovine brain gangliosides and GM2 were used as standards for neolacto-series gangliosides and ganglio-
series gangliosides respectively. A doublet band a represents sialosyl K2C3-lacto-neotetraosylceramide; a doublet band b represents sialosyl
K2C6-lacto-neotetraosylceramide; band c, sialosyl K2C3-lacto-norhexaosylceramide; band d, sialosyl-K2C6-lacto-norhexaosylceramide [25,26].
After development, the HPTLC plate was sprayed with orcinol-H2SO4 reagent, and bands were made visible by heating.
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showed that BFA-treated cells were arrested in the G0/G1
phase (79.5% of cells in the G0/G1 phase, 6.0% in S, and
14.5% in G2/M versus 65.1%, 18.6%, and 16.3%, in control
culture after 1 day of treatment), and then the cells gradually
initiated apoptosis (Fig. 3). Fragmentation of DNA, which is
a marker for apoptosis, was observed after 3 days of treat-
ment (Fig. 4A).
No apparent di¡erentiation-inducing activity of BFA was
observed at 0.02 Wg/ml, and cytotoxic e¡ects of BFA appeared
at 0.2 Wg/ml.
3.3. E¡ect of forskolin on di¡erentiation-inducing activity of
BFA
BFA has been reported to disrupt the Golgi apparatus and
to subsequently inhibit protein secretion [16]. To investigate
the implications of this in the molecular mechanism of BFA-
induced di¡erentiation of HCT 116 cells, we examined the
e¡ect of forskolin, which has been shown to inhibit and re-
verse the e¡ects of BFA on the Golgi apparatus and to reverse
BFA’s block on protein secretion [17], on the di¡erentiation-
inducing activity of BFA. Forskolin (50 WM) did not a¡ect the
BFA-induced change in ganglioside pattern (data not shown),
morphological di¡erentiation, or DNA fragmentation (Fig.
4B). This suggests that the e¡ects of BFA on the Golgi appa-
ratus and protein secretion are independent of its di¡erentia-
tion-inducing activity.
4. Discussion
We have shown that human epithelial carcinoma cells can
be induced to di¡erentiate into terminally di¡erentiated cells
by remodeling the ganglioside pattern by using BFA, which
a¡ects ganglioside biosynthesis, suggesting that ganglioside
remodeling could be a potent target for di¡erentiation therapy
of cancer. Functional di¡erentiation in BFA-treated cells has
not yet been examined. However, even if functional di¡eren-
Fig. 2. Induction of di¡erentiation in HCT 116 cells by ganglioside remodeling. HCT 116 cells were treated with 0.1 Wg/ml BFA. A: Changes
in de novo biosynthesis of gangliosides after 6 h of treatment. Ganglioside fractions corresponding to 1U107 cells were applied. Bands were
made visible by a BAS 2000 imaging analyzer. B: Morphological changes in treated cells under phase-contrast light microscopy (magni¢cation,
U90). BFA-treated cells formed a typical epithelial sheet with bright cellular contact after 1 day of treatment. C: Ganglioside pro¢les of treated
cells. Ganglioside fractions corresponding to 5U106 cells were applied. After development, the HPTLC plate was sprayed with orcinol-H2SO4
reagent, and bands were made visible by heating.
C
Fig. 3. Cell cycle analysis of BFA-treated HCT 116 cells. Cells were
cultured in the absence or presence of 0.1 Wg/ml BFA for the indi-
cated periods of time. The cells were ¢xed, stained with PI, and an-
alyzed by cyto£uorometry.
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tiation is induced in cancer cells, the cells do not necessarily
lose their malignant phenotypes [18,19]. It seems to be very
important in cancer cell di¡erentiation to induce immortalized
cancer cells to die a natural death. Therefore, we assessed
terminal di¡erentiation of cancer cells by apoptosis that is
induced after morphological di¡erentiation of the cells.
In a wide variety of mammalian cells, BFA has been re-
ported to inhibit protein transport beyond the endoplasmic
reticulum (ER)-Golgi system and to cause disassembly of
the Golgi apparatus and its mixing with the ER, but not to
a¡ect the trans-Golgi network [16]. However, it is considered
that BFA’s induction of di¡erentiation exists not for these
activities but for ganglioside pattern changes, especially in-
crease in GM3, for two reasons: neither the e¡ect of BFA
on ganglioside biosynthesis nor the terminal di¡erentiation-
inducing activity of BFA was inhibited by forskolin, and
exogenously added GM3 also induced terminal di¡erentiation
in HCT 116 cells (H. Nojiri, unpublished results). It was sug-
gested that di¡erentiation of human colonic carcinoma cells is
also promoted by speci¢c ganglioside. Forskolin did not a¡ect
BFA-induced ganglioside changes in our study, which sug-
gests that membrane tra⁄c between Golgi stacks remained
inhibited after morphological recovery of the Golgi apparatus.
NaBT has been reported to elevate CMP-sialic acid:lacto-
sylceramide sialyltransferase (GM3 synthase) activity, and to
increase GM3 levels in human epithelial carcinoma cells
[18,20]. This suggests that NaBT might exert its di¡erentia-
tion-inducing activity by increasing GM3 levels. An appreci-
able increase in GM3 was also observed before morphological
changes both in NaBT-treated HCT 116 cells and in BFA-
treated cells. As there is a threshold concentration of ganglio-
side for induction of di¡erentiation [3,4], an NaBT-induced
increase of GM3 in HCT 116 cells might not be enough for
induction of su⁄cient di¡erentiation. Other well-known dif-
ferentiation inducers such as dimethylsulfoxide, retinoic acid,
and 12-O-tetradecanoylphorbol 13-acetate also increase gan-
gliosides that have di¡erentiation-inducing activity [2^4].
Some di¡erentiation inducers might exert their activities via
induction of gangliosides that have di¡erentiation-inducing
activity. Conversely, drugs that can induce such bioactive gan-
gliosides could be di¡erentiation inducers.
It has been reported that although the mechanism of anti-
tumor activity of BFA remains unknown, BFA exhibits stron-
ger antitumor activity in vitro against a variety of leukemia
and solid tumor cell lines of human origin than against those
of murine origin [21]. This antitumor e¡ect might be due to
induction of apoptosis (terminal di¡erentiation) by BFA-in-
duced ganglioside change, and the selectiveness might be due
to di¡erences in susceptibility of the cells to the ganglioside
change. Because ganglioside change in di¡erentiation of hu-
man cancer cell is di¡erent from that in murine cancer cells
[2,22], gangliosides that induce terminal di¡erentiation in hu-
man cancer cells might therefore not necessarily induce di¡er-
entiation in murine cancer cells.
In addition to increasing GM3, BFA inhibits biosynthesis of
neolacto-series glycolipid core chains [11]. This speci¢city of
BFA seems to be very important, because neolacto-series gly-
colipids include gangliosides with sialyl Lex and sialyl Lea
antigens, which are ligands for E-selectin and are closely re-
lated to cancer metastasis [23]. Furthermore, neolacto-series
gangliosides accumulate in human colonic adenocarcinoma
and are either low or not found in normal colonic mucosa
[6,24]. Inhibition of biosynthesis of neolacto-series ganglio-
sides might also be signi¢cant for induction of di¡erentiation
in human colonic carcinoma cells. Studies focusing on the
molecular mechanism by which speci¢c gangliosides induce
cancer cell di¡erentiation are now in progress.
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